ETRM : Summary for EnteroMedics Inc. - Yahoo Finance

U.S. Markets close in 1 hr 34 mins

EnteroMedics Inc. (ETRM)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.30+0.15 (+2.10%)
As of 2:26PM EST. Market open.
People also watch
PULMBIOCIDXGGLBSXGTI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close7.15
Open7.50
Bid7.16 x 300
Ask7.19 x 100
Day's Range7.08 - 7.59
52 Week Range0.04 - 30.41
Volume518,289
Avg. Volume11,820,221
Market Cap31.05M
Beta2.82
PE Ratio (TTM)-0.07
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire30 minutes ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating EnteroMedics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • PR Newswire7 hours ago

    EnteroMedics Regains Compliance With Nasdaq Listing Requirement

    ST. PAUL, Minn., Feb. 21, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that on February 17, 2017, Nasdaq issued a determination that the company has evidenced compliance with all requirements for continued listing on The Nasdaq Capital Market and, accordingly, the listing qualifications matter has been closed. The Company also announced that it will host a conference call on Tuesday, March 7, 2017 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2016 and to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy.

  • PR Newswire12 days ago

    EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

    ST. PAUL, Minn., Feb. 9, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of three-year data from the Company's VBLOC DM2 Study of vBloc® Neurometabolic Therapy in obese patients with Type 2 diabetes. The publication, entitled "Vagal Nerve Block for Improvements in Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus: Three-Year Results of the VBLOC DM2 Study," was published in the Journal of Diabetes and Obesity and is available online here.